Novabay Pharmaceuticals, INC. (NBY) — DEF 14A Filings
All DEF 14A filings from Novabay Pharmaceuticals, INC.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
NovaBay Pivots from Liquidation with $6M Lazar Investment, Seeks Major Shareholder Approvals
— Sep 23, 2025 Risk: high
NovaBay Pharmaceuticals, Inc. (NBY) is seeking stockholder approval for a series of critical proposals at its 2025 Annual Meeting on October 16, 2025, primarily -
NovaBay Pharmaceuticals Files 2025 Proxy Statement
— Mar 19, 2025 Risk: low
NovaBay Pharmaceuticals, Inc. filed its definitive proxy statement on March 19, 2025, for its annual meeting of stockholders scheduled for April 16, 2025. The f -
NovaBay Pharmaceuticals, Inc. Files DEF 14A Proxy Statement
— Apr 18, 2024 Risk: low
NovaBay Pharmaceuticals, Inc. (NBY) filed a Proxy Statement (DEF 14A) with the SEC on April 18, 2024. NovaBay Pharmaceuticals, Inc. filed a DEF 14A proxy statem
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX